Multinational pharmaceutical corporations are pressuring the U.S. government to directly block cheaper, generic varieties of life-saving drugs in India.

The Indian government is “reviewing patented drugs of foreign firms to see if so-called compulsory licenses, which in effect break exclusivity rights, can be issued for some of them to bring down costs,” according to a Reuters article published Thursday, which cites two senior government officials.

The review affects up to a dozen varieties of drugs used to treat cancer, diabetes, hepatitis and HIV and signifies a move to make them more affordable.